勁拓股份(300400.SZ):公司半導體專用設備包含用於半導體封測和硅片製造製程的設備產品
格隆匯6月6日丨有投資者在投資者互動平台向勁拓股份(300400.SZ)提問,“貴公司大力展半導體封裝設備,請問2023年以來,半導體的設備銷量如何,貴公司今年生產經營狀況如何?”
公司回覆稱,公司半導體專用設備包含用於半導體封測和硅片製造製程的設備產品,對標美國、德國等國技術和產品成熟的品牌企業,面向下游封測廠商和硅片製造廠商。公司重視半導體專用設備業務發展,積極推進半導體專用設備客户拓展、提升銷售規模,具體情況及經營成果需以公司於巨潮資訊網披露的定期報吿、臨時性公吿為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.